Ge Long Hui·2026-02-28 06:42Core Viewpoint - BeiGene achieved a revenue of $5.34 billion in 2025, representing a year-on-year increase of 40%, with product revenue of $5.28 billion, slightly exceeding previous management guidance of $5-5.3 billion [1] Group 1: Financial Performance - The company reported a net profit of $290 million, recovering from a loss of $640 million in the previous year, marking a turnaround in recurring business [1] - Management expects revenue to reach $6.2-6.4 billion in 2026, with GAAP operating profit projected at $700-800 million [1] Group 2: Product Performance - Zanubrutinib generated $3.93 billion in revenue for the year, up 49% year-on-year, with U.S. sales of $2.8 billion (up 45%), European sales of $600 million (up 66%), and Chinese sales of $340 million (up 33%) [1] - In Q4 2025, Zanubrutinib revenue was $1.15 billion, reflecting a quarter-on-quarter increase of 10% and a year-on-year increase of 38% [1] - Tislelizumab achieved $740 million in revenue for the year, a 19% increase year-on-year, with Q4 2025 revenue of $180 million, down 5% quarter-on-quarter but up 18% year-on-year [1] - Revenue from cooperative products in China reached $620 million, a 20% increase year-on-year, driven by growth in Duzallo and Belantamab Mafodotin [1] Group 3: Future Catalysts - Key catalysts for 1H26 include the approval of Sotorasib for R/R MCL in the U.S. and interim analysis for Zanubrutinib in 1L MCL Phase III trials [2] - In 2H26, the company plans to submit an accelerated approval application for BTK CDAC based on Phase II clinical data for R/R CLL and initiate Phase III trials for Sotorasib in combination therapy for multiple myeloma [2] - The revenue forecasts for FY26 and FY27 are maintained at $6.4 billion and $7.1 billion, respectively, with slight adjustments to net profit estimates reflecting increased R&D expenditures [2] - The target price is set at HKD 212.09, maintaining an "outperform" rating based on a DCF model with a WACC of 9% and a perpetual growth rate of 4% [2]